Trials / Completed
CompletedNCT00610363
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rilonacept | Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks. |
| OTHER | Placebo (for Rilonacept) | Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-02-07
- Last updated
- 2017-05-02
- Results posted
- 2017-05-02
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00610363. Inclusion in this directory is not an endorsement.